RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA

Clinical trials for RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA trials appear

Sign up with your email to follow new studies for RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for tough blood cancers: experimental drug HRS-3738 enters human testing

Disease control Ongoing

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

Matched conditions: RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA

Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control

Last updated Jun 08, 2026 13:03 UTC

RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA

Get alerted when new RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA trials appear

New hope for tough blood cancers: experimental drug HRS-3738 enters human testing